[Correspondence] The PREOPANC-2 trial in resectable and borderline resectable pancreatic cancer

We congratulate Quisette P Janssen and colleagues on the phase 3 PREOPANC-2 trial.1 PREOPANC-2 was the successor of the phase 3 PREOPANC-1, which showed improved overall survival following pre-operative chemoradiotherapy and surgery versus surgery for patients with anatomically resectable or borderline resectable pancreatic ductal adenocarcinoma. In light of the superiority for post-operative FOLFIRINOX versus gemcitabine and multiple rationales for pre-operative…